Lupus is a chronic disease that can cause inflammation and pain in any part of the body. It’s an autoimmune disease, which ...

Dr Sudhir Karmacharya, a lupus specialist at the National Center for Rheumatic Diseases (NECRD), stated that lupus is more ...

In milder cases this can be accomplished by relatively simple means: a limited cutaneous rash may be amenable to ... However, for the vast majority of lupus flares the initial treatment has ...

The National Institutes of Health has awarded an Oklahoma Medical Research Foundation scientist a $4.1 million grant to study ...

It is highly debilitating – with a range of symptoms extending from rash and arthritis to seizures ... phase 3 for SLE and phase 2 for cutaneous lupus erythematosus (CLE) – also partnered ...

There are around 250,000 people in the EU with SLE, characterised by widespread organ damage, joint swelling, rashes ... by a new indication in acute lupus nephritis. Prospects for anifrolumab ...

Healthy living is a goal for most. Yet, much too often individuals unknowingly engage in habits that hinder this goal.

An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of ...

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.

A new study found that low or absent disease activity, hydroxychloroquine (HCQ) use, and gradual reduction of GC dosing can ...

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

Cutaneous lupus erythematosus is associated with an increased risk for ASCVD, similar to the risk seen in association with SLE.